Clinical Trial Update: Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating antibody-drug conjugates in combination with adebrelimab for HER2-negative advanced breast cancer, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: Advanced Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING